Valeant Pharmaceuticals acquires dermatology company
ALISO VIEJO, Calif. Drug maker Valeant Pharmaceuticals said Friday that it had acquired a dermatology company based in Poland.
Valeant purchased privately held Emo-Farm for approximately $28 million, saying the acquisition would expand Valeant’s base in Poland into multiple therapeutic categories. Emo-Farm’s portfolio includes several topical drugs and more awaiting regulatory approval.
Under the deal, Valeant will acquire Emo-Farm’s 13,000-sq.-ft. manufacturing plant.
“The acquisition of Emo-Farm is consistent with our business plan strategy,” Valeant chairman and CEO J. Michael Pearson stated. “We now have a platform from which we can launch various topical products, including our dermatology pipeline, and become a premier dermatology company in the countries in which we operate.”
OSI Pharmaceuticals EVP to present portfolio at diabetes and obesity conference
MELVILLE, N.Y. OSI Pharmaceuticals, Inc. announced Thursday that Anker Lundemose, M.D., EVP of OSI Pharmaceuticals will present at the Canaccord Adams Conference in New York, N.Y. on Tuesday, May 12, 2009 at 8:40 a.m. (Eastern Time).
Lundemose will provide an overview on the company’s diabetes/obesity product portfolio and business developments.
OSI Pharmaceuticals discover, develop and commercialize high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
FDA grants priority review to Prevnar 13
COLLEGEVILLE, Pa. The Food and Drug Administration has granted priority review to Wyeth Pharmaceuticals’ application for the pneumococcal vaccine Prevnar 13 (diphtheria CRM protein).
The company submitted the application for the vaccine, a 13-valent conjugate vaccine, on March 31.
Wyeth said it is seeking approval for Prevnar 13 for the prevention of invasive pneumococcal disease and otitis media caused by the 13 serotypes in the vaccine in children ages 2 months to 5 years. Prevnar 13 includes six serotypes in addition to the seven in the earlier version of Prevnar.
“Since its launch in 2000, our seven-valent pneumococcal vaccine, Prevnar, has significantly reduced the incidence of pneumococcal disease among infants and young children in the United States,” Wyeth Pharmaceuticals EVP vaccine research and development Emilio Emini said. “Recently, however, disease due to pneumococcal serotypes not found in Prevnar, particularly serotype 19A, have increased in prevalence in many regions of the world and are a significant public health concern.”